- Home
- MLTX vs SRRK Comparison
MLTX vs SRRK Comparison
Compare MLTX & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- SRRK
- Stock Information
- Founded
- MLTX 2021
- SRRK 2012
- Country
- MLTX Switzerland
- SRRK United States
- Employees
- MLTX N/A
- SRRK N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MLTX Health Care
- SRRK Health Care
- Exchange
- MLTX Nasdaq
- SRRK Nasdaq
- Market Cap
- MLTX 2.8B
- SRRK 3.2B
- IPO Year
- MLTX N/A
- SRRK 2018
- Fundamental
- Price
- MLTX $49.67
- SRRK $38.87
- Analyst Decision
- MLTX Strong Buy
- SRRK Strong Buy
- Analyst Count
- MLTX 7
- SRRK 6
- Target Price
- MLTX $73.33
- SRRK $42.17
- AVG Volume (30 Days)
- MLTX 426.9K
- SRRK 1.4M
- Earning Date
- MLTX 08-06-2025
- SRRK 08-07-2025
- Dividend Yield
- MLTX N/A
- SRRK N/A
- EPS Growth
- MLTX N/A
- SRRK N/A
- EPS
- MLTX N/A
- SRRK N/A
- Revenue
- MLTX N/A
- SRRK N/A
- Revenue This Year
- MLTX $103.42
- SRRK N/A
- Revenue Next Year
- MLTX N/A
- SRRK $502.60
- P/E Ratio
- MLTX N/A
- SRRK N/A
- Revenue Growth
- MLTX N/A
- SRRK N/A
- 52 Week Low
- MLTX $31.42
- SRRK $6.76
- 52 Week High
- MLTX $58.26
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- MLTX 62.21
- SRRK 62.99
- Support Level
- MLTX $46.37
- SRRK $36.91
- Resistance Level
- MLTX $49.29
- SRRK $38.15
- Average True Range (ATR)
- MLTX 1.91
- SRRK 1.85
- MACD
- MLTX 0.13
- SRRK 0.29
- Stochastic Oscillator
- MLTX 70.19
- SRRK 92.45
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.